<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Anaptysbio, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/anaptysbio-inc</link>
    <description>Latest news and press releases for Anaptysbio, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 04 May 2026 20:15:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/anaptysbio-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835463378dffbe2df0e2e13.webp</url>
      <title>Anaptysbio, Inc.</title>
      <link>https://6ix.com/company/anaptysbio-inc</link>
    </image>
    <item>
      <title>Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-to-participate-at-the-hc-wainwright-2nd-annual-royalty-company-virtual-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-to-participate-at-the-hc-wainwright-2nd-annual-royalty-company-virtual-conference</guid>
      <pubDate>Mon, 04 May 2026 20:15:00 GMT</pubDate>
      <description>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 1:30pm ET. To register for the conference, p</description>
    </item>
    <item>
      <title>Vanda Pharmaceuticals announces the publication of &quot;Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis&quot; in NEJM Evidence</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-imsidolimab-for-generalized-pustular-psoriasis-in-nejm-evidence-1</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-imsidolimab-for-generalized-pustular-psoriasis-in-nejm-evidence-1</guid>
      <pubDate>Tue, 28 Apr 2026 23:12:00 GMT</pubDate>
      <description>Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled &quot;Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis&quot; in New England Journal of Medicine (NEJM) Evidence1.</description>
    </item>
    <item>
      <title>Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaros-anticipatory-breach-claim</guid>
      <pubDate>Fri, 24 Apr 2026 19:40:00 GMT</pubDate>
      <description>Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reductionTrial to adjudicate Anaptys’ contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro’</description>
    </item>
    <item>
      <title>Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations</guid>
      <pubDate>Mon, 20 Apr 2026 13:15:00 GMT</pubDate>
      <description>Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business. Anaptys will now exclusively manage</description>
    </item>
    <item>
      <title>Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-dollar100-million-stock-repurchase-plan-and-provides-a-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-dollar100-million-stock-repurchase-plan-and-provides-a-business-update</guid>
      <pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
      <description>Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial</description>
    </item>
    <item>
      <title>First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/first-tracks-biotherapeutics-the-planned-spin-off-of-anaptys-secures-commitments-of-dollar145-million-in-private-placement</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/first-tracks-biotherapeutics-the-planned-spin-off-of-anaptys-secures-commitments-of-dollar145-million-in-private-placement</guid>
      <pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
      <description>Inclusive of $80 million in proceeds from private placement by leading investorsFirst Tracks Biotherapeutics to launch with $180 million in cash and two-year</description>
    </item>
    <item>
      <title>Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-board-of-directors-approves-spin-off-of-first-tracks-biotherapeutics</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-board-of-directors-approves-spin-off-of-first-tracks-biotherapeutics</guid>
      <pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
      <description>Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-marketStockholders will receive one share of</description>
    </item>
    <item>
      <title>Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-provides-update-on-business-separation-and-announces-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-provides-update-on-business-separation-and-announces-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Tue, 03 Mar 2026 21:15:00 GMT</pubDate>
      <description>Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-AprilPhase 1b enrollment ongoing in celiac disease and trial cohort initiated in eosinophilic esophagitis for ANB033, a CD122 antagonistGSK announced strong commercial performance for Jemperli, growing &gt;13% quarter-over-quarter to $343 million in Q4 2025, implying a ~$1.4 billion annualized run rateExpect to achieve &gt;$390 million in annualized Jemp</description>
    </item>
    <item>
      <title>Anaptys Announces Participation at Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-upcoming-investor-211500820</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-upcoming-investor-211500820</guid>
      <pubDate>Thu, 05 Feb 2026 21:15:00 GMT</pubDate>
      <description>SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026, New York, NY Format – Fireside chat and 1x1 investor meetingsDat</description>
    </item>
    <item>
      <title>Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-files-motion-dismiss-tesaro-230000539</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-files-motion-dismiss-tesaro-230000539</guid>
      <pubDate>Thu, 08 Jan 2026 23:00:00 GMT</pubDate>
      <description>Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to dismiss Tesaro’s anticipatory breach of contract claim in Delaware Chancery Court related to pending litigation between Anaptys, GSK, and TESARO, Inc. (“Tesaro”) regarding their Collaboration and Exc</description>
    </item>
    <item>
      <title>Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</guid>
      <pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
    </item>
    <item>
      <title>Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/vanda-announces-submission-of-biologics-license-application-to-the-fda-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/vanda-announces-submission-of-biologics-license-application-to-the-fda-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis</guid>
      <pubDate>Mon, 15 Dec 2025 12:00:00 GMT</pubDate>
      <description>Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36RA regulator commonly seen in GPP patients due to IL36RN gene mutations.</description>
    </item>
    <item>
      <title>Anaptys Announces Participation in December Investor Conferences</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-december-investor-conferences-2025-11-25</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-december-investor-conferences-2025-11-25</guid>
      <pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
    </item>
    <item>
      <title>Anaptys Announces $100 Million Stock Repurchase Plan</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-100-million-stock-repurchase-plan-2025-11-21</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-100-million-stock-repurchase-plan-2025-11-21</guid>
      <pubDate>Fri, 21 Nov 2025 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
    </item>
    <item>
      <title>Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-initiates-litigation-against-tesaro-gsk-subsidiary-2025-11-21</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-initiates-litigation-against-tesaro-gsk-subsidiary-2025-11-21</guid>
      <pubDate>Fri, 21 Nov 2025 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
    </item>
    <item>
      <title>Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-phase-2-trial-rosnilimab-did-not-meet-primary-or-secondary</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-phase-2-trial-rosnilimab-did-not-meet-primary-or-secondary</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>Rosnilimab was safe and well tolerated with similar adverse event rates vs. placeboObserved expected pharmacology, including ~90% depletion of pathogenic T</description>
    </item>
    <item>
      <title>Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-third-quarter-2025-financial-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-third-quarter-2025-financial-results-and-provides-business-update</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic</description>
    </item>
    <item>
      <title>Anaptys Announces Participation in November Investor Conferences</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-november-investor-conferences-2025-11-04</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-participation-november-investor-conferences-2025-11-04</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
    </item>
    <item>
      <title>Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-new-positive-phase-2b-trial-results-rosnilimab-rheumatoid-arthritis</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-new-positive-phase-2b-trial-results-rosnilimab-rheumatoid-arthritis</guid>
      <pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
      <description>New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to</description>
    </item>
    <item>
      <title>Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025</title>
      <link>https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-late-breaking-oral-presentation-complete-phase-2b-data-rosnilimab</link>
      <guid isPermaLink="true">https://6ix.com/company/anaptysbio-inc/news/anaptys-announces-late-breaking-oral-presentation-complete-phase-2b-data-rosnilimab</guid>
      <pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
      <description>SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative</description>
    </item>
  </channel>
</rss>